Ifosfamide extrapyramidal neurotoxicity

Cancer

Volumn 68, Issue 1, 1991, Pages 72-75

  Anderson, Norwood R ^a,b   Tandon, Deepak S ^a,b  

^a Cancer Center of Boston   (United States)

^b NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; FUROSEMIDE; IFOSFAMIDE; MANNITOL; MESNA; METOCLOPRAMIDE; THEOPHYLLINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADENOCARCINOMA; BASAL GANGLIA DISEASES; CASE REPORT; HUMAN; IFOSFAMIDE; LUNG NEOPLASMS; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGE; NEOPLASMS, MULTIPLE PRIMARY;

EID: 0026353860     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19910701)68:1<72::AID-CNCR2820680114>3.0.CO;2-#     Document Type: Article

References (30)

1. The role of ifosfamide in testicular cancer
2. VP‐16 plus ifosfamide plus cisplatin as salvage treatment in refractory germ cell tumors
3. Ifosfamide in testicular cancer: The Indiana University experience
4. European experience with ifosfamide in lymphomas
5. Experience with ifosfamide combinations in malignant lymphomas
6. Experience of a German multicenter study group with ifosfamide in small cell lung cancer
7. Ifosfamide in the treatment of non small cell lung cancer
8. Mitomycin, ifosfamide, and cisplatin in non‐small cell lung cancer: Treatment good enough to compare
9. European experience with ifosfamide in non‐small cell lung cancer
10. The role of ifosfamide in the treatment of sarcomas
11. The control of ifosfamide‐induced hematuria with N‐acetylcysteine in patients with advanced carcinoma of the lung
12. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II study with 151 patients
13. Phase II study of ifosfamide combined with mesna uroprotection in advanced non‐small cell lung carcinoma and other solid tumors
14. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors
15. Prediction of encephalopathy associated with ifosfamide/mesna administration
16. CNS‐side effects induced by ifosfamide‐mesna in children with osteosarcoma
17. Irreversible encephalopathy with ifosfamide/mesna (Letter)
18. Central nervous system toxicity following ifosfamide treatment for children with malignant solid tumors (Abstr)
19. Central nervous system toxicity following treatment of pediatric patients with ifosfamide/mesna
20. Central nervous system side effects following ifosfamide monotherapy of advanced renal carcinoma
21. Blurring of vision due to ifosfamide (Letter)
22. Dechloroethylation of ifosfamide and neurotoxicity (Letter)
23. Ifosfamide: Pharmacology, safety and therapeutic potential
24. Ifosfamide in cervical cancer: Early phase II results in patients with advanced or recurrent disease (Abstr)
25. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors
26. Ifosfamide/mesna related encephalopathy: A case report with a possible role of phenobarbital in enhancing neurotoxicity
27. Treatment of metastatic renal cancer with ifosfamide and mesna with and without irradiation
28. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cisdiamminedichloroplatinum (II) therapy
29. Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi‐institutional phase II trial
30. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study